Dataset Information

Target Landscape of Clinical Kinase Inhibitors

ABSTRACT: Here, we provide a comprehensive overview of the selectivity profiles of 242 kinase inhibitors currently in clinical trials. We screened available inhibitors against human protein kinases by using the Kinobead technology resulting in a drug matrix identifying the druggable kinome and related proteins.

INSTRUMENT(S): Orbitrap Fusion, Q Exactive HF, LTQ Orbitrap Elite, Q Exactive

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Bernhard Kuster

PROVIDER: MSV000081932 | MassIVE | Fri Jan 12 21:28:00 GMT 2018

SECONDARY ACCESSION(S): PXD005336

REPOSITORIES: MassIVE

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Publications

The target landscape of clinical kinase drugs.

Klaeger Susan S Heinzlmeir Stephanie S Wilhelm Mathias M Polzer Harald H Vick Binje B Koenig Paul-Albert PA Reinecke Maria M Ruprecht Benjamin B Petzoldt Svenja S Meng Chen C Zecha Jana J Reiter Katrin K Qiao Huichao H Helm Dominic D Koch Heiner H Schoof Melanie M Canevari Giulia G Casale Elena E Depaolini Stefania Re SR Feuchtinger Annette A Wu Zhixiang Z Schmidt Tobias T Rueckert Lars L Becker Wilhelm W Huenges Jan J Garz Anne-Kathrin AK Gohlke Bjoern-Oliver BO Zolg Daniel Paul DP Kayser Gian G Vooder Tonu T Preissner Robert R Hahne Hannes H Tõnisson Neeme N Kramer Karl K Götze Katharina K Bassermann Florian F Schlegl Judith J Ehrlich Hans-Christian HC Aiche Stephan S Walch Axel A Greif Philipp A PA Schneider Sabine S Felder Eduard Rudolf ER Ruland Juergen J Médard Guillaume G Jeremias Irmela I Spiekermann Karsten K Kuster Bernhard B

Science (New York, N.Y.) 20171201 6367

Kinase inhibitors are important cancer therapeutics. Polypharmacology is commonly observed, requiring thorough target deconvolution to understand drug mechanism of action. Using chemical proteomics, we analyzed the target spectrum of 243 clinically evaluated kinase drugs. The data revealed previously unknown targets for established drugs, offered a perspective on the "druggable" kinome, highlighted (non)kinase off-targets, and suggested potential therapeutic applications. Integration of phosphop ...[more]

PMID: 29191878

Similar Datasets

Project description:<p>We have used a "chemistry first" approach to discover druggable acquired vulnerabilities that arised in the pathogenesis of non-small cell lung cancer (NSCLC). We screened chemical libraries (~200,000 compounds) for chemical toxins that killed subsets of NSCLC but not normal human lung epithelial cells (HBECs). We first screened a panel of 12 NSCLC lines that represented a variety of known oncogenotypes and identified chemicals with large Z scores and appropriate properties including re-supply, chemistry, and reproducible drug response phenotypes. This was then narrowed down to a list of 202 chemicals and 18 drugs with known targeting (henceforth called "Precision Oncology Probe Set", or POPS). These, and a panel of 30 clinically available drugs, targeted therapies, and drug combinations, already in use or in trials for NSCLC treatment, were then tested on a panel of 96 NSCLC lines for their drug response phenotypes in 12-point dose response curves. This information was analyzed using scanning ranked KS (Kolmogorov-Smirnov) and elastic net biostatistics approaches to identify molecular biomarkers (mutations, mRNA expression, copy number variation, protein expression, and metabolomics) which could predict for sensitivity or resistance to a particular chemical toxin or treatment regimen. From this we have discovered that: our approach identifies already known molecular biomarker of drug sensitivities (e.g. EGFR mutations and EGFR TK inhibitors); many clinically available chemotherapy agents have molecular biomarkers predicting preclinical model drug responses; the POP set of chemical toxins provides novel drug response phenotype patterns in the large NSCLC panel different from those found with clinically available agents including a therapeutic window; many of the POP toxins only hit a small percentage (~5%) of the NSCLC panel but the POP set as a whole provides "coverage" of the entire NSCLC panel; there are simple, one or 2 component molecular biomarkers (mutations, mRNA expression) that predict responses to the different chemical toxins in the NSCLC panel; and that the molecular biomarkers provide some information on the targets and pathways involved in response to the chemical toxins. Thus, we have identified a group of chemical toxins with selectivity for subsets of NSCLC and associated tumor molecular biomarkers to facilitate their development for precision medicine, and also, in some cases, information on the targets and pathways interdicted by these chemical compounds. In addition, we have discovered NSCLC predictive biomarkers for clinically available agents.</p>